Elotuzumab is an immunotherapy called a monoclonal antibody. It was approved for use in November of 2015 to be used with lenalidomide and dexamethasone. Researchers are now testing elotuzumab with another drug in the same class of immunomodulator drugs called pomalidomide to see if it has similar impact in the treatment on myeloma. In this study, researchers are comparing pomalidomide and low-dose dexamethasone vs. pomalidomide, low-dose dex and elotuzumab. The trial aims to include over 120 patients and is open in 11 locations in the US. To learn more about this clinical trial, click here: Elotuzumab, Pom, Dex for Relapsed/Refractory Myeloma